Pulmonary Gas Exchange in Candidates for Surgical Treatment of Ischaemic Heart Disease

Respiration ◽  
1978 ◽  
Vol 35 (3) ◽  
pp. 136-147 ◽  
Author(s):  
P. Jebavý ◽  
J. Fabián ◽  
M. Henzlová ◽  
A. Belán
Keyword(s):  
Heart Disease ◽  
Surgical Treatment ◽  
Gas Exchange ◽  
Ischaemic Heart Disease ◽  
Pulmonary Gas Exchange

Pulmonary Gas Exchange after Propranolol in Patients with Ischaemic Heart Disease

Respiration ◽  
1980 ◽  
Vol 40 (1) ◽  
pp. 38-46
Author(s):  
P. Jebavý ◽  
J. Ressl ◽  
R. Jandová
Keyword(s):  
Heart Disease ◽  
Gas Exchange ◽  
Ischaemic Heart Disease ◽  
Pulmonary Gas Exchange

Surgical treatment of patients with abdominal aortic aneurysm and ischaemic heart disease

2021 ◽  
Vol 27 (3) ◽  
pp. 85
Author(s):  
L. N. Ivanov ◽  
A. L. Maksimov ◽  
S. A. Mukhin ◽  
E. V. Chebotar' ◽  
S. V. Naumov ◽  
...  
Keyword(s):  
Abdominal Aortic Aneurysm ◽  
Heart Disease ◽  
Surgical Treatment ◽  
Aortic Aneurysm ◽  
Ischaemic Heart Disease ◽  
Abdominal Aortic

Perfusion: a view from the British Heart Foundation

Perfusion ◽  
2002 ◽  
Vol 17 (4) ◽  
pp. 241-242
Author(s):  
Charles George
Keyword(s):  
Cardiovascular Disease ◽  
Heart Disease ◽  
Surgical Treatment ◽  
Ischaemic Heart Disease ◽  
British Heart Foundation ◽  
Prevention And Treatment ◽  
Individual Project ◽  
Heart Foundation

The British Heart Foundation was established 40 years ago with the aim of playing a major role in the fight against cardiovascular disease. Despite spectacular advances in the surgical treatment of congenital and ischaemic heart disease, there is a continued need for research into the causes, diagnosis, prevention and treatment. The Foundation will continue to support professors, training fellowships and individual project and programme grants to meet these needs.

OBJECTIVE EVALUATION OF RESULTS OF SURGICAL TREATMENT OF ISCHÆMIC HEART DISEASE 1

1972 ◽  
Vol 2 (S1) ◽  
pp. 14-18
Author(s):  
Richard S. Ross ◽  
C. Richard Conti ◽  
Bertram Pitt ◽  
J. O'Neal Humphries
Keyword(s):  
Heart Disease ◽  
Surgical Treatment ◽  
Ischaemic Heart Disease ◽  
Objective Evaluation

Elevated Tissue Factor and Tissue Factor Pathway Inhibitor Circulating Levels in Ischaemic Heart Disease Patients

1998 ◽  
Vol 79 (03) ◽  
pp. 495-499 ◽  
Author(s):  
Anna Maria Gori ◽  
Sandra Fedi ◽  
Ludia Chiarugi ◽  
Ignazio Simonetti ◽  
Roberto Piero Dabizzi ◽  
...  
Keyword(s):  
Heart Disease ◽  
Ischaemic Heart Disease ◽  
Tissue Factor ◽  
Plasma Levels ◽  
Tissue Factor Pathway Inhibitor ◽  
Common Source ◽  
Previous Myocardial Infarction ◽  
Control Subjects ◽  
Tissue Factor Pathway ◽  
Circulating Levels

SummarySeveral studies have shown that thrombosis and inflammation play an important role in the pathogenesis of Ischaemic Heart Disease (IHD). In particular, Tissue Factor (TF) is responsible for the thrombogenicity of the atherosclerotic plaque and plays a key role in triggering thrombin generation. The aim of this study was to evaluate the TF/Tissue Factor Pathway Inhibitor (TFPI) system in patients with IHD.We have studied 55 patients with IHD and not on heparin [18 with unstable angina (UA), 24 with effort angina (EA) and 13 with previous myocardial infarction (MI)] and 48 sex- and age-matched healthy volunteers, by measuring plasma levels of TF, TFPI, Prothrombin Fragment 1-2 (F1+2), and Thrombin Antithrombin Complexes (TAT).TF plasma levels in IHD patients (median 215.4 pg/ml; range 72.6 to 834.3 pg/ml) were significantly (p<0.001) higher than those found in control subjects (median 142.5 pg/ml; range 28.0-255.3 pg/ml).Similarly, TFPI plasma levels in IHD patients were significantly higher (median 129.0 ng/ml; range 30.3-316.8 ng/ml; p <0.001) than those found in control subjects (median 60.4 ng/ml; range 20.8-151.3 ng/ml). UA patients showed higher amounts of TF and TFPI plasma levels (TF median 255.6 pg/ml; range 148.8-834.3 pg/ml; TFPI median 137.7 ng/ml; range 38.3-316.8 ng/ml) than patients with EA (TF median 182.0 pg/ml; range 72.6-380.0 pg/ml; TFPI median 115.2 ng/ml; range 47.0-196.8 ng/ml) and MI (TF median 213.9 pg/ml; range 125.0 to 341.9 pg/ml; TFPI median 130.5 ng/ml; range 94.0-207.8 ng/ml). Similar levels of TF and TFPI were found in patients with mono- or bivasal coronary lesions. A positive correlation was observed between TF and TFPI plasma levels (r = 0.57, p <0.001). Excess thrombin formation in patients with IHD was documented by TAT (median 5.2 μg/l; range 1.7-21.0 μg/l) and F1+2 levels (median 1.4 nmol/l; range 0.6 to 6.2 nmol/l) both significantly higher (p <0.001) than those found in control subjects (TAT median 2.3 μg/l; range 1.4-4.2 μg/l; F1+2 median 0.7 nmol/l; range 0.3-1.3 nmol/l).As in other conditions associated with cell-mediated clotting activation (cancer and DIC), also in IHD high levels of circulating TF are present. Endothelial cells and monocytes are the possible common source of TF and TFPI. The blood clotting activation observed in these patients may be related to elevated TF circulating levels not sufficiently inhibited by the elevated TFPI plasma levels present.

Sign in / Sign up

Export Citation Format

Share Document